CMG 1A46
Alternative Names: 1A46; CMG-1A46Latest Information Update: 14 Nov 2024
Price :
$50 *
At a glance
- Originator Chimagen Biosciences
- Developer Chimagen Biosciences; GSK
- Class Antineoplastics; Immunotherapies; Trispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Lymphoid leukaemia; Non-Hodgkin's lymphoma
- Preclinical Autoimmune disorders